Quantitative T1 and T2 measurements of metastatic bone lesions in prostate cancer patients: MR fingerprinting versus standard quantitative MRI
Mihaela Rata1,2, Nina Tunariu1,2, Yun Jiang3, Julie Hughes1, Georgina Hopkinson1, Erica Scurr1, Jessica M Winfield1,2, Vikas Gulani3, Dow-Mu Koh1,2, and Matthew R Orton1,2
1Radiology/MRI Unit, Royal Marsden NHS Foundation Trust, Sutton/London, United Kingdom, 2Division of Radiotherapy and Imaging, Institute of Cancer Research, Sutton/London, United Kingdom, 3Radiology, University of Michigan, Ann Arbor, MI, United States
Magnetic resonance fingerprinting (MRF) generates fast, co-registered quantitative maps from a single acquisition. This prospective study evaluates MRF-derived measures of treatment-induced T1 and T2 changes in prostate cancer patients with metastatic bone disease, by comparison with existing quantitative T1 and T2 measurements. This study demonstrated a good correlation of MRF-derived T1 and T2 changes with existing quantitative methods, supporting the use of MRF for faster measurements in bone lesions.
This abstract and the presentation materials are available to members only;
a login is required.